Boehringer Ingelheim reports Phase III survodutide results in obesity and type 2 diabetes

Key highlights
  • In the 755-participant SYNCHRONIZE-2 trial, 76 weeks of survodutide produced up to 13.1% average weight loss versus 3.1% with placebo, using the efficacy estimand.
  • Up to 79.3% of participants on survodutide lost at least 5% of body weight, compared with 32.7% on placebo.
  • HbA1c fell by up to 1.21 percentage points from a baseline of 7.4%; waist circumference decreased by 11.1 cm.
  • Gastrointestinal adverse events led to treatment discontinuation in 18% of survodutide recipients versus 1.2% on placebo.

Trial results

Boehringer Ingelheim reported that Phase III SYNCHRONIZE-2 met its co-primary endpoints in adults with overweight or obesity and type 2 diabetes. After 76 weeks, average weight loss reached 13.1% with survodutide versus 3.1% with placebo, using the efficacy estimand. At least 5% weight loss was achieved by up to 79.3% of participants on survodutide and 32.7% on placebo. Results were presented at the European Association for the Study of Diabetes meeting and published in The New England Journal of Medicine.

Metabolic measures and safety

HbA1c decreased by up to 1.21 percentage points from a baseline of 7.4%, compared with 0.03 points on placebo. Waist circumference fell by 11.1 cm versus 3.5 cm, and insulin sensitivity measures improved. Gastrointestinal events, mostly mild to moderate, were the most common adverse events; they led to treatment discontinuation in 18% of survodutide recipients and 1.2% of placebo recipients.

Further studies

A SYNCHRONIZE-1 substudy found preferential reductions in visceral and liver fat; muscle accounted for no more than 10% of total tissue lost. Survodutide is investigational, and its efficacy and safety have not been established. Boehringer plans to report SYNCHRONIZE-CVOT results later this year and has launched the Phase III SYNCHRONIZE-T2D trial.

Source: Boehringer Ingelheim

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

16 October 2026
EMA recommends Eli Lilly’s oral GLP-1 Foundayo (orforglipron) for weight management and type 2 diabetes

Oral orforglipron showed 5–11% weight loss at 72 weeks and 1.2–1.9 percentage‑point HbA1c reductions; CHMP opinion now goes to the European Commission for an EU licence.

9 November 2026
Boehringer Ingelheim’s SCOVELLA receives positive CVMP opinion

The EU recommendation concerns a proposed treatment to lower insulin levels and associated laminitis risk in horses with Equine Metabolic Syndrome.

28 October 2026
Boehringer Ingelheim reports survodutide meets cardiovascular safety endpoint

The Phase III trial found no increased risk of major cardiovascular events versus placebo, alongside improvements in weight, blood pressure and waist circumference.

7 June 2026
Boehringer Ingelheim: Survodutide Phase III shows up to 34% visceral and 63% liver fat reduction with limited lean mass loss

Phase III data show targeted visceral and liver fat reductions with minimal lean mass loss and sustained weight loss in obesity and MASLD populations.

12 November 2026
Lilly starts construction of $3.5bn obesity-medicine plant in Pennsylvania

The Fogelsville facility will make injectable medicines, including investigational retatrutide, and is expected to be operational by 2031.